TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of Acarbose as Treatment for Pediatric Non-alcoholic Fatty Liver Disease (NAFLD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age:10-18 years old~* Liver biopsy proven NAFLD. NAFLD defined histologically as greater than 5% hepatic macrovesicular steatosis with any degree of chronic inflammation and hepatic fibrosis; clinical definition requires that other liver diseases associated with fatty liver be excluded.~* Insulin resistance with HOMA-IR score \>3.0~* Hepatic steatosis \>5% wet weight on hepatic proton magnetic resonance spectroscopy (1H-MRS)~* INR \<1.2; Conjugated Bilirubin \<2umol/L and Albumin \>35gm/L~Exclusion Criteria:~* Type 1 or 2 diabetes mellitus~* Treatment with oral hypoglycemic agents~* Ongoing participation in a formal weight loss program or interventional clinical trial~* Panhypopituitarism and genetic causes of obesity i.e. Prader-Willi syndrome~* Alcohol consumption \>20 g/day~* Serum creatinine above normal range for age~* History of previous or predisposition to intestinal obstruction~* Pre-existing gastrointestinal disease i.e. inflammatory bowel disease; celiac disease~* Drugs that influence energy metabolism, intestinal transit, substrate metabolism

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cell Transplantation in MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Inflammatory forms of MS~   1. Relapsing-remitting MS (RRMS) patients~  2. Secondary progressive MS (SPMS) patients with continued relapses~  3. Primary progressive MS (PPMS) patients with enhancing MRI lesions and positive CSF (oligoclonal banding)~2. Age 18-50 years~3. Disease duration \>= 2 and \>= 10 years~4. EDSS 3.0 - 6.5~5. Progression, continued relapses or worsening MRI after at least a year of attempted therapy evidenced by:~   1. Increase of \>= 1 EDSS point (if baseline EDSS \<= 5.0) or 0.5 EDSS points (if baseline EDSS \>= 5.5), or quantifiable, objective evidence of equivalent progression~  2. \>= 1 moderate-severe relapses in past 18 months~  3. \>= 1 Gadolinium enhancing lesions (double or triple dose Gadolinium)~  4. \>= 1 new T2 lesion~  5. For PPMS only, \>= 1 Gadolinium enhancing lesions~6. Has given informed consent to participate in the study.~Exclusion Criteria:~1. SPMS without ongoing relapses~2. PPMS without positive CSF or Gadolinium enhancing lesions~3. \<= 3 months since treatment with any immunosuppressive therapy~4. \<=1 month since last treatment with interferon-B or glatiramer acetate~5. Corticosteroid treatment \<= 30 days~6. Relapse \<= 60 days~7. History of cancer or clinical or laboratory results indicative of severe systemic diseases, including infection for HIV, Hepatitis B or C~8. Any metallic or electronic device that precludes from undergoing MRI~9. Pregnancy or lactation~10. Current treatment with an investigational therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- autologous mesenchymal stem cell (Type: EXPERIMENTAL): A single infusion of up to 2 million cells per Kg of autologous mesenchymal stem cells vs suspension media. The treatment will be reversed at 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Robotic Assisted Cochlear Implantation Feasibility Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Geographically and physically able to attend scheduled evaluations and follow-up appointments~* Indicated for cochlear implantation~* Age 18 years or older~* Fluent in German or French~* Sufficient facial recess size ( \> 2.5 mm between the facial nerve and chorda tympani)~Exclusion Criteria:~* Pregnancy~* Anatomical malformation of the middle or inner ear or unusual facial nerve course~* Lack of compliance with any inclusion criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Minimally invasive robotic cochlear implantation with custom device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DASH - Decision Making in Adolescent Sexual Health

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. participating in the youth reporting center;~2. be aged 14 to 18;~3. be proficient in English~4. consent to be re-contacted 3 and 6 months post-intervention;~5. must have the fully informed consent of a parent or legal guardian;~6. must give their personal fully informed assent to participate.~Exclusion Criteria:~1. History of brain injury or brain related medical problems;~2. Currently on any psychotropic medications (e.g., neuroleptics, anticonvulsants);~3. Female subjects must not be pregnant (as indicated by a negative pregnancy test on scan day);~4. fMRI contra-indications (e.g., non-removable metallic implants, claustrophobia).

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Motivational interviewing (Type: EXPERIMENTAL): None
- Behavioral skills training (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Colectomy with ileostomy~   a. Ileostomy alone with less than 30 cm of small bowel resected i. A diverting ileostomy is permitted~2. Stable disease activity with no or mild inflammation felt not to significantly impact gastrointestinal (GI) output.~3. Any of the following:~   1. Need for IV fluids \>2x/month~  2. Intake of \> 1.5 liters of oral fluid daily~4. GI output of \> 1.3 liters in a 24-hour period for three days each week during a 14 day screening period (does not need to be consecutive days)~5. Stable doses of anti-diarrheal agents, octreotide or Gattex~6. Stable doses of anti-inflammatory agents and/or antibiotics~7. Willing to comply with study visits and assessments, including product intake.~Exclusion:~1. Chronic renal insufficiency glomerular filtration rate (GFR) \< 40~2. Significant chronic liver disease altering fluid balance~3. Uncontrolled flare of inflammatory disease~   a. (Inflammation can be present but at a stable at least partly controlled level) b. An anticipated change in medication in the next 3 months i. May be included 8 weeks after changing medications if they are stable c. Anticipated gastrointestinal surgery in the subsequent 3 months i. May be included if they are 4 months out from surgery and stable~4. Diabetes~5. Use of Lactulose/Mannitol solution is contraindicated~6. Current Diagnosis of Cancer~   a. May be included if they are 4 or more months out from cancer therapy (i.e. chemotherapy, etc.)~7. Aversion to the taste of enterade® or inability to take the product as instructed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- amino acid mixture beverage (Type: EXPERIMENTAL): amino acid based hydration beverage. It will be given 8 oz, twice daily for the first 4 weeks of randomized blinded intervention. It will be given in same dose during 4 week open label intervention.
- glucose based sports drink (Type: ACTIVE_COMPARATOR): glucose based hydration beverage. It will be given 8oz, twice daily for the first 4 weeks of randomized blinded intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Partial Left Ventricular Support in Advanced Heart Failure

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with ischaemic or dilated cardiomyopathy aged 18 to 80 years.~* Symptoms categorised by INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) at level 3-6 despite optimal tolerated medical therapy. Practically this includes patients who are in hospital or managing at home with substantial dependence on hospital care.~* Peak VO2 \<15ml/kg/min with respiratory exchange ratio\>1 on cardiopulmonary exercise testing OR a 6-minute walking distance \<300m OR inability to perform an exercise test due to the severity of heart failure.~* Informed consent obtained prior to entering the study.~Exclusion Criteria:~* Cause of heart failure due to or associated with uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, or active myocarditis~* Body surface area \<1.2M2 or \>2.3M2, or body mass index \>32 kg/M2.~* Severe chronic obstructive pulmonary disease as evidenced by forced expiratory volume in 1 second \<50% of predicted.~* History of pulmonary hypertension with maintained pulmonary vascular resistance measured \> 4 Wood units or transpulmonary gradient \>14mmHg.~* Pregnancy.~* Evidence of intrinsic hepatic disease defined as liver enzyme levels \> 5 times the upper limit of normal within 4 days before enrolment, severe liver dysfunction, cirrhosis or portal hypertension.~* Occurrence of stroke within 90 days before enrolment.~* Impairment of cognitive function or presence of any form of irreversible dementia.~* Recent history of psychiatric disease (including severe drug or alcohol abuse) that is likely to impair compliance with the study protocol.~* Platelet count \<50 x103mm3 within 24 hours before enrolment.~* Creatinine clearance \< 30ml/min.~* High probability of non-compliance.~* The patient is deemed unsuitable by the clinical team for other reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Synergy (Type: None): Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team for implantation of a CircuLite Synergy left ventricular assist device.
- Control (Type: None): Patients in the Synergy group will have severe advanced heart failure (see inclusion criteria) and will have been selected by their clinical team to continue current optimal medical and device therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent from legally acceptable guardian~* PPHN or hypoxemic respiratory failure associated with:~  * Idiopathic PPHN~ * Meconium aspiration syndrome~ * Respiratory distress syndrome~ * Sepsis~ * Pneumonia~* Greater than or equal to 35 weeks gestation~* Age at enrollment less than 72 hours~* Moderate hypoxemic respiratory failure, with 12\<OI\<35 (oxygenation index, calculated as FiO2 \* mean airway pressure \* 100 / postductal PaO2)~* Absence of structural heart disease (except patent ductus arteriosus, atrial septal defect \<1cm, or muscular ventricular septal defect \< 2mm)~* Absence of lethal congenital anomaly~* Not participating in another concurrent experimental study~Exclusion Criteria:~* Prior or immediate need for iNO or ECMO~* Profound hypoxemia: qualifying PaO2 \<30 mmHg, from a blood gas drawn within 30 minutes of starting study drug infusion.~* Hypotension: Mean arterial pressure \<35 mmHg~* Congenital heart disease, except patent ductus arteriosus, atrial septal defect \<1cm, or muscular ventricular septal defect \<2mm~* Congenital diaphragmatic hernia or lung hypoplasia syndromes, diagnosed on the basis of prolonged oligohydramnios~* Active seizures~* Apgar score of \<3 at 5 minutes~* Bleeding diathesis~* Receipt of any other experimental drug or device~* Receipt of any prohibited concurrent medication:~  * Potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole and protease inhibitors)~ * Endothelin antagonists (e.g. Tracleer/bosentan)~ * Intravenous nitrates or nitric oxide donors~* Known hereditary degenerative retinal disorders such as retinitis pigmentosa.~* In the opinion of the investigator, a subject who is not likely to complete the study or would be considered inappropriate for the study, for any reason.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: f

Study Arms:
- Intravenous Sildenafil (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): 0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blind Child Melatonin Treatment Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Children and adults 5 to 20 years old~* Blindness for at least one year, verified by an ophthalmologic exam~* Ability to comply with the requirements of the experimental protocol~* And no clinically significant abnormalities (other than blindness) on a general physical examination.~* Subjects must be competent to sign informed consent if age 18 or older. Parents and subjects will be interviewed together and, when appropriate (for example, subject is age 18 or older), separately as well.~Exclusion Criteria:~* Abnormal heart, liver or kidney function; intractable seizure disorders~* Significant laboratory abnormalities on CBC, Comprehensive Metabolic set, or UA (dip stick method)~* Pregnancy; sexual activity in post-pubertal females not using a recognized and valid contraceptive method~* A current Axis I psychiatric or substance abuse disorder according to the DSM-IV Manual ; OR~* External demands that limit the ability to maintain a regular schedule, e.g. night shift work.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 20 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Subjects will be given up to 0.5 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
- 2 (Type: EXPERIMENTAL): Subjects will be given up to 10 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.
- 3 (Type: EXPERIMENTAL): Subjects will be given up to 20 mg daily. If the treatment works, the dose will be reduced gradually until the lowest, effective dose is identified. If the treatment is unsuccessful, the subject will be taken off treatment and later enrolled in a different treatment plan.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Effects of 3 Day Preoperative Immunonutrition in Well-nourished Patients With Gastrointestinal (GI) Cancer Undergoing Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with GI cancer (stomach, pancreas, small and large bowel and rectum) histologically proven~* Well nourished patients as defined by a total score of \<3 on the nutritional screening tool NRS-2002 (46) (Appendix III)~* Patients who are \>= 18 years of age;~* Patients who have signed a written Informed Consent (Appendix I) prior to admission to the study;~* Patients who have an ECOG performance status of 0, 1 or 2 (Appendix II).~* Patients able to orally consume 750 mL or more of liquid a day prior to surgery~Exclusion Criteria:~* Patients who have co-morbid conditions, uncontrolled metabolic conditions or psychiatric conditions that might make tolerance or evaluation of the feeding formula difficult;~* Patients who are pregnant;~* Patients with cardiac failure as defined by the Goldman classification class\>3~* Patients with respiratory failure (FEV\<0.8l/sec)~* Patients with renal failure (Cr \>= 3mg/dl or dialysis patients)~* Patients with hepatic dysfunction (Child \>A)~* Patients suffering from an intestinal obstruction or ileum~* Patients with an Hb level of \<=8 g/dL experiencing gastrointestinal hemorrhaging~* Patients with HIV, HCV, HBV~* Patients requiring immunosuppression treatments~* Patients undergoing emergency surgery~* Other patients determined by a study investigator to be inappropriate for enrolment in this study

- Gender: None
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutritional product (Type: ACTIVE_COMPARATOR): Oral nutritional supplement containing immuno nutrients
- Isocaloric control (Type: PLACEBO_COMPARATOR): Isocaloric and isonitrogenous control without immuno nutrients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: HL2351 CAPS Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented molecular diagnosis of NALP3 mutation or diagnosis of CAPS based on sign and symptom~* Diagnosis of CAPS based on signs and symptoms~* Current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids~Exclusion Criteria:~* Patient been diagnosed with a hereditary periodic fever syndrome or autoinflammatory disease other than CAPS~* Patients whose disease is inadequately controlled on current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HL2351 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have signed an inform consent document~* Have histologic or cytologic diagnosis of breast cancer with evidence of unresectable locally recurrent or metastatic disease~* Have not received any prior chemotherapy for locally recurrent or metastatic disease~* Have not had adjuvant or neoadjuvant taxane therapy within 12 months prior to assignment to study treatment~* Age 18 years or older at time of informed consent~Exclusion Criteria:~* Have any clinical evidence of central nervous system (CNS) metastases~* Have a history of seizure~* Have had a major surgical procedure within 4 weeks prior to assignment to study treatment~* Have had a minor surgical procedure, placement of an access device, or fine needle aspiration within 7 days prior to assignment to study treatment~* Have symptomatic peripheral vascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enzastaurin + Bevacizumab + Paclitaxel (Type: EXPERIMENTAL): Participants randomized to this arm (Arm A) will receive enzastaurin, paclitaxel and bevacizumab until disease progression.~Prior to randomization, a safety lead-in will be conducted in 6 participants who will be treated according to Arm A for 2 cycles (1 cycle = 28 days). Only after an acceptable safety analysis of the safety lead-in, will other participants be randomized to Phase 2 (either Arm A or Arm B). In Phase 2, participants from the safety lead-in will continue treatment according to Enzastaurin + Bevacizumab + Paclitaxel (Arm A).
- Bevacizumab + Paclitaxel + Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this arm (Arm B) will receive bevacizumab, paclitaxel and placebo until disease progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues